Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
体軸型脊椎関節炎に対するビメキズマブの有効性と安全性: 2つのフェーズ3無作為化対照試験結果
Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595
Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.
Keywords:
強直性脊椎炎に注目した脊椎関節炎の新規治療
Expert Opin Biol Ther. 2023 doi: 10.1080/14712598.2022.2156283
This review aimed to discuss the emerging agents for the treatment of axSpA.
Keywords:
活動性強直性脊椎炎患者におけるbimekizumabの安全性と 有効性: フェーズIIb無作為化対照試験とそのオープンラベル延長試験 からの3年結果
Arthritis Rheumatol. 2022;74:1943–58
In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.
Keywords:
活動性乾癬性関節炎患者におけるbimekizumabの安 全性と有効性: フェーズIIb無作為化対照試験とその オープンラベル延長試験の3年結果
Arthritis Rheumatol. 2022 doi: 10.1002/art.42280
This study highlighted that the safety of bimekizumab in patients with PsA over 3 years of treatment was consistent with the previous 48-week results, as well as other recently published studies of IL-17 inhibitors in PsA patients.
Keywords:
TNF阻害薬に効果不十分または不耐な活動性乾癬性 関節炎患者におけるビメキズマブ: 無作為化二重盲検 プラセボ対照フェーズ3試験 (BE COMPLETE)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0
This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.
Keywords:
生物学的製剤未治療乾癬性関節炎患者におけるビメ キズマブ: 無作為化, 二重盲検, フェーズ3 試験 (BE OPTIMAL)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9
This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.
Keywords:
活動性強直性脊椎炎患者におけるビメキズマブの安全性と有効性: フェーズ2b 無作為化対照試験とそのオープンラベル試験の3年結果
Arthritis Rheumatol 2022 doi: 10.1002/art.42282
Bimekizumab is associated with sustained, long-term efficacy in r-axSpA patinets across three years of treatment. In coming to this conclusion, investigators sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in active r-axSpA.
Keywords:
活動性乾癬性関節炎におけるビメキズマブの安全性と有効性: フェーズ 2b 無作為化コントロール対照試験とオープンラベル延長試験の3年結果
Arthritis Rheumatol 2022 doi: 10.1002/art.42280
In this investigation bimekizumab was associated with a sustained ACR50 improvement. This was highlighted following the attempt to describe the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients
Keywords:
乾癬性関節炎患者におけるbimekizumabの症状や障害に対する3年間の効果: BE ACTIVE試験結果
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac353
Here bimekizumab was associated with long-term reductions in disease activity and disease impact on patients with PsA. This investigation set out to evaluate the long-term effects of bimekizumab treatment on the key symptoms of PsA and the resulting impact on patient function and HRQoL.